Featured Article

Ken Getz of Tufts CSDD Discusses RBQM Study Conducted with CluePoints and PwC

In part 1 of this video interview series with Ken Getz, executive director and research professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine and Steve Young, chief science officer, CluePoints, Getz touches on the findings from a recent study on RBQM adoption.

Guide

NEW: The Ultimate Guide to Modern, Regulatory-Grade RBQM

Download
Blog
RBQM in Practice: From Principles to Proportionate Oversight
  • Regulatory guidance clearly defines what RBQM is intended to achieve. The harder question is how those...
Read More
Blog
What Sponsors Actually Look for in CRO RBQM
  • And why inspection readiness is now a commercial differentiator. RBQM is often discussed as a regulatory...
Read More
Blog
From Fragmentation to a Scalable RBQM Operating Model
  • Why tools alone aren’t enough, and what CROs need instead. Most CROs don’t lack RBQM capability....
Read More
CluePoints RBQM Live25 On-Demand Recordings are now Available! Banner - ROI of RBQM, ICH E6(R3) in Practice, Future of AI